This panel discussion guides IO biotechs through drug development amidst a saturated landscape. The panelists address challenges and suggest pathways for advancement in the field. The webinar discussion is a rebroadcast from the 2025 IO360º summit.
Topics addressed:
- Critical planning decisions for development pathways
- Investor expectations during fundraising
- Generating positive market response by finding different ways to deploy technology
- Partnering with large pharma and working with other biotechs to complement existing capabilities
- Build versus partner: the mission-critical personnel to have in-house for success
About IO360º, the webinar’s associated conference:
IO360˚ is an annual conference that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. To learn more about IO360, visit io360summit.com.
Moderators
Roy Baynes, MD, PhD
EVP & CMO
Eikon Therapeutics
Sharon Benzeno, PhD, MBA
Chief Commercial Officer, Immune Medicine
Adaptive Biotechnologies
Theresa LaVallee, PhD
Chief Scientific & Development Officer
Coherus Oncology
Rachel Humphrey, MD
President and Founding CEO
Normunity
Speakers
Sarah Warren, PhD
Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation
Kite Pharma / Gilead Sciences
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.